In this landmark women-only study, patients assigned to receive the boosted PI were more likely to discontinue treatment for adverse events.
Landmark randomized trial produces clear evidence of benefits of earlier ART initiation.
Discontinuation rates due to toxicity significantly lower with lower atazanavir/ritonavir dose.
Treatment switch associated with lower rate of discontinuation for adverse events and improvements in renal and bone markers.
Switch to EVG/COBI/FTC/TAF from TDF-containing regimens also associated with increased bone mineral density and increases in total cholesterol, LDL cholesterol, and triglycerides.
Week 24 virologic and immunologic outcomes were similar between arms; doravirine was associated with fewer CNS adverse events vs efavirenz.
Substantial hyperbilirubinemia with RTV-containing regimens.
However, all 3 cases of virologic rebound and 1 case of central nervous system escape occurred in the monotherapy switch arm.
In this case-controlled study, HIV-related factors predicted risk of bone loss in first 96 weeks but not during later follow-up.
Treatment generally well tolerated with evidence of improvements in markers of HBV and liver disease in this coinfected population.
A low CD4+ cell count was also significantly associated with differences in hip bone mineral density changes.